Pan Xin-Bin, Huang Shi-Ting, Chen Kai-Hua, Jiang Yan-Ming, Zhu Xiao-Dong
Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, P.R. China.
Medicine (Baltimore). 2019 Feb;98(7):e14512. doi: 10.1097/MD.0000000000014512.
Identification of predictive factors of chemotherapy use and assessment of the roles of these factors in prognosis will aid therapeutic decision-making in stage II nasopharyngeal carcinoma (NPC).Using logistic regression, we retrospectively assessed factors predicting chemotherapy use in 251 stage II (2010 UICC/AJCC staging system) NPC patients. Five-year overall survival (OS), locoregional-free survival (LRFS), and distant metastasis-free survival (DMFS) were analyzed based on the predictive factors.Logistic regression found that N1 stage was an independent factor predicting chemotherapy use in stage II NPC patients. However, 5-year OS (96.5% vs 94.9%, P = .564), LRFS (98.2% vs 96.9%, P = .652), and DMFS (95.9% vs 97.6%, P = .560) did not differ between N0 and N1 stage patients. Moreover, addition of chemotherapy use did not improve treatment outcomes in N1 stage compared with radiotherapy alone.N1 stage predicted chemotherapy use in stage II NPC patients. But, the addition of chemotherapy did not provide a survival benefit.
确定化疗使用的预测因素并评估这些因素在预后中的作用，将有助于II期鼻咽癌（NPC）的治疗决策。我们采用逻辑回归，回顾性评估了251例II期（2010年UICC/AJCC分期系统）NPC患者中预测化疗使用的因素。基于这些预测因素分析了5年总生存期（OS）、无局部区域复发生存期（LRFS）和无远处转移生存期（DMFS）。逻辑回归发现N1期是II期NPC患者化疗使用的独立预测因素。然而，N0期和N1期患者之间的5年OS（96.5%对94.9%，P = 0.564）、LRFS（98.2%对96.9%，P = 0.652）和DMFS（95.9%对97.6%，P = 0.560）并无差异。此外，与单纯放疗相比，N1期患者增加化疗使用并未改善治疗结果。N1期可预测II期NPC患者的化疗使用。但是，增加化疗并未带来生存获益。
